Merck & Co (MRK) Aktsia Kursus
Merck & Co Kursus
Käive kasvas 5,7 % aastas viimase 19 aasta jooksul 64,93 B USD-ni. Kasum aktsia kohta kasvas 7,0 % aastas viimase 19 aasta jooksul. Merck & Co netomarginaal on nüüd 28,1 %, tõusnud 26,8 %-lt mõni aasta tagasi. Merck & Co pakub praegu umbes 2,33 % dividenditootlust. Väljamaksesuhe on umbes 45 % kasumist. Dividend kasvas 4,1 % aastas viimase 19 aasta jooksul. Analüütikute hinnasihi mediaan on 144,00 USD, st üle praegust hinda 2,2 %. 35 analüütikust 26 soovitab osta — üldine konsensus on Osta.
Merck & Co aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Merck & Co ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Merck & Co aktsia kohta
The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.
Merck & Co Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Merck & Co Inc in the market are Johnson & Johnson, Pfizer Inc, Novartis AG, and Bristol-Myers Squibb Company.
Merck & Co Inc is a renowned pharmaceutical company with a rich history and notable background. Established in 1891, Merck & Co Inc has been dedicated to enhancing global health and improving people's lives. The company has evolved into one of the leading players in the pharmaceutical industry, specializing in research, development, and manufacturing of innovative medications and vaccines. Merck & Co Inc has proactively contributed to medical advancements, from pioneering treatments for diseases like HIV/AIDS to addressing various health challenges. With a commitment to scientific excellence and patient well-being, Merck & Co Inc continues to shape the future of healthcare worldwide.
Merck & Co Inc, a leading pharmaceutical company, has achieved significant milestones throughout its history. The company's notable achievements include the development and launch of groundbreaking drugs like Gardasil, a vaccine for preventing cervical cancer, and Keytruda, an innovative immunotherapy for treating various types of cancer. Merck & Co Inc has also contributed to medical advancements with its research and development efforts, resulting in breakthroughs in areas such as HIV/AIDS treatment and vaccines. The company's commitment to improving global health has resulted in partnerships and initiatives aimed at tackling diseases like malaria and Ebola. Merck & Co Inc continues to make strides in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.
Merck & Co Inc is primarily present in several countries and regions across the world. The company has a strong global presence, with operations in the United States, Europe, Asia-Pacific, Latin America, and Africa. Merck & Co Inc has established a significant presence in key markets such as the United States, Germany, Japan, China, and Brazil. With its wide international footprint, Merck & Co Inc is committed to delivering its innovative healthcare solutions to patients and healthcare professionals worldwide.
Merck & Co Inc represents a strong commitment to scientific innovation, integrity, and improving global health. As a leading pharmaceutical company, Merck aims to discover, develop, and provide high-quality healthcare solutions. The company's corporate philosophy revolves around putting patients first, valuing diversity and inclusion, and taking responsibility for environmental sustainability. Merck is dedicated to delivering innovative medicines and vaccines, ensuring affordability and access for patients worldwide. With a focus on research, collaboration, and ethical business practices, Merck strives to make a positive impact on society and enhance the well-being of individuals around the globe.
Analüütikud määravad Merck & Co aktsiale keskmiseks hinnasihi 140,42 USD (mediaan: 144,00 USD), mis on −6,5 % viimase hinna suhtes. Konsensus põhineb 35 analüütiku hinnangul.
35 analüütikut hindavad praegu Merck & Co aktsiat: 26 soovitab osta, 9 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Merck & Co teenib tulu 67,02 B USD ja kasumit aktsia kohta 2,65 USD.
Praeguse kursiga kaubeldakse Merck & Co aktsiaga 126,26 EUR (140,93 USD) juures.
Merck & Co aktsia (MRK) on noteeritud 11 börsil, sh: NYSE (MRK), London (0QAH.L), SIX (Zürich) (MRK1.SW), XETRA (6MK.DE), Frankfurt (6MK.F), München (6MK.MU), Düsseldorf (6MK.DU), Hamburg (6MK.HM).
Merck & Co Inc is one of the leading global pharmaceutical companies focused on the discovery, development, and marketing of drugs, vaccines, and biologics for a variety of diseases and disorders. The company is headquartered in Kenilworth, New Jersey and operates worldwide in over 140 countries.
oodatav Merck & Co käive on 67,02 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Merck & Co kasum on 6,60 B USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Merck & Co jaoks on praegu 53,09. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Merck & Co aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Merck & Co jaoks on praegu 5,23. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Merck & Co aktsia jaoks.
Eulpooli kvaliteedinäitaja Merck & Co jaoks on 7/10.
Merck & Co ISIN on US58933Y1055. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Merck & Co WKN on A0YD8Q. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Merck & Co ticker on MRK. Ticker-sümbol kasutatakse Merck & Co aktsiate kauplemiseks börsil.
Merck & Co aktsia
Merck & Co konkurendid
Merck & Co Börsiticker
Merck & Co FIGI
Kõik teised näitajad ja analüüsid Merck & Co kohta sügavamalt
Meie Merck & Co-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Merck & Co. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: